Michaelson Jennifer's Form 4/A amendment
AmendedCullinan Therapeutics, Inc. (CGEM) · filed Aug 26, 2021
- Accession no.
- 0000899243-21-034312
- Filed
- Aug 26, 2021
- Trade date
- Aug 18, 2021
- Filing delay
- 8 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
- Original filed
- Aug 24, 2021
This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $110.6K. It was filed 8 days after the trade.
This amendment replaces 0000899243-21-034025 (filed Aug 24, 2021).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Michaelson JenniferCIK 0001838061 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2021 | Common Stock | MOption exerciseAcquired | +4,000 | $4.30 | +$17,200 | 26,911 | Direct | |
| Aug 18, 2021 | Common Stock | SSaleDisposed | −2,863 | $27.50F2 | −$78,732.5 | 24,048 | Direct | |
| Aug 18, 2021 | Common Stock | SSaleDisposed | −1,137 | $28.07F3 | −$31,915.59 | 22,911 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 18, 2021 | Common Stock | MOption exerciseDisposed | −4,000 | $0.00 | $0 | 225,978 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021.
- F2
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $26.91 to $27.89. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F3
The price reported in Column 4 is a weighted average price. The shares were purchased in multiple transactions at prices ranging from $27.92 to $28.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
- F4
25% of the shares vested on July 4, 2020, and the remaining shares shall vest in 36 equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
Remarks
Chief Development Officer, Biologics This amended Form 4 is being filed to include an explanatory note that the reported sales were made pursuant to a plan established pursuant to Rule 10b5-1 on April 29, 2021.